Trends and influencing factors of hospitalization costs among patients with tetanus: a retrospective analysis based on a tertiary hospital in Northeast China, 2013-2025
This retrospective analysis of 319 tetanus patients at a Northeast China tertiary hospital from 2013 to 2025 reveals that hospitalization costs are significantly higher for mechanically ventilated patients and are primarily driven by length of stay, ventilation duration, disease severity, and pulmonary complications, highlighting the need for optimized clinical pathways and enhanced vaccination strategies to mitigate the economic burden.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Tetanus is a rare but terrifying infection caused by a bacterium that enters the body through a break in the skin. Once inside, the bacteria release a powerful poison that locks the muscles into painful, uncontrollable spasms. Because these spasms can stop a person from breathing, the disease often requires weeks of intensive care in a hospital, where patients are kept alive by machines and heavy sedation. While vaccines have made the disease much less common in many parts of the world, it still strikes, particularly among farmers and workers who handle soil, and the treatment is incredibly expensive. For families and hospitals alike, understanding exactly what drives up the cost of this treatment is crucial, not just for saving money, but for figuring out how to manage care more effectively when the disease does strike.
Researchers at a major hospital in Northeast China decided to look closely at the financial reality of treating tetanus over a thirteen-year period, from 2013 to 2025. They gathered the medical records and billing data for 319 adult patients who had been admitted for the disease. To make sense of the numbers, the team split the patients into two distinct groups: those who were treated without needing a breathing machine, and those who required mechanical ventilation, a life-support system that breathes for the patient when their own muscles are too stiff to work. By comparing these two groups, the researchers could see how the severity of the illness changed the financial picture. They found that the cost difference was staggering. The patients who needed the breathing machine stayed in the hospital much longer and incurred costs that were roughly four and a half times higher than those who did not need the machine. For the non-ventilated group, the typical cost was around 4,800 US dollars, while the ventilated group faced a typical bill of over 21,000 US dollars.
The study also tracked how these costs changed over time. In both groups, the money spent on treatment rose steadily from 2013 until 2018, reaching a peak, and then began to fall. The researchers identified that the largest chunk of the bill always came from medications, including drugs to stop the muscle spasms, painkillers, and antibiotics. The reason for the rise and subsequent fall in costs was tied to changes in how these drugs were priced and how hospitals were paid. Around 2018, the government introduced new policies that lowered the price of key sedative drugs and changed the way hospitals were reimbursed for care, which helped drive the total cost down in the later years of the study.
When the researchers dug deeper to find what specifically made the bills go up, they found different answers for the two groups. For patients who did not need a breathing machine, the single biggest factor was simply how long they stayed in the hospital. Every extra day added a significant amount to the total cost. The presence of a lung infection that developed while in the hospital also pushed costs higher, as did the patient's age. For the patients on the breathing machine, the length of time they needed the machine was the most powerful driver of cost. The longer a patient stayed on the ventilator, the more the bill grew. Other factors for this group included the severity of the tetanus, the development of pneumonia specifically linked to the breathing tube, and the patient's gender, with men tending to have slightly higher costs than women, likely due to differences in body weight and lung health.
The findings suggest that while the disease itself is the root cause, the duration of treatment and the management of complications are the levers that control the financial burden. The researchers noted that preventing lung infections and finding ways to safely shorten the time patients spend on breathing machines or in the hospital could significantly reduce expenses. However, they emphasized that the most effective way to lower the overall cost to society is to prevent the disease from happening in the first place. By ensuring that high-risk groups, such as farmers and construction workers, are fully vaccinated, the number of severe cases requiring expensive, long-term hospital care can be drastically reduced, sparing families and healthcare systems from these heavy financial strains.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.